PruVen Capital
Palo Alto, United States19
60M
16
4.75
0.16
- Areas of investment
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 19
- Lead investments
- 0
- Rounds per year
- 4.75
- Follow on index
- 0.16
- Investments by industry
- Insurance (8)
- InsurTech (5)
- Health Care (5)
- FinTech (4)
- Software (4) Show 37 more
- Investments by region
- United States (16)
- Brazil (2)
- Indonesia (1)
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 5
- Avg. valuation at time of investment
- 128M
- Group Appearance index
- 1.00
- Strategy success index
- 0.20
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Clever Care Health Plan Inc. | 15 Mar 2023 | Health Care, Health Insurance, Insurance | Late Stage Venture | 42M | United States, California |
| Deed | 09 Dec 2021 | Enterprise Software, Communities, Social Impact, Cause Marketing | Early Stage Venture | 10M | United States, New York, New York |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AgileRL , a London, UK-based startup accelerating the development of reinforcement learning for training AI models | Jul 1, 2026 | Machine Learning, Reinforcement Learning, RLOps Platform | - | 7500000 USD | UK-based startup accelerating the development of reinforcement learning for training AI models, a London |
| AIRIA | Jul 30, 2025 | Enterprise, Government, Operational AI, Spatial Intelligence | - | - | New York |
| EydisBio | Aug 30, 2024 | Autoimmune Diseases, Inflammatory Diseases, Pharmaceutical, TAK1 Inhibitors | - | 2600000 USD | Durham, North Carolina |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.